

IN THE CLAIMS:

Please delete claims 1 through 10 and add new claims 11 through 20 as follows:

~~11.~~ Use of the R-enantiomers of arylpropionic acids or their derivatives for the preparation of medicaments which inhibit the NF- $\kappa$ B activation cascade and therefore are suited to the treatment of diseases which may be influenced therapeutically beneficial by the inhibition of NF- $\kappa$ B production.

~~12.~~ Use according to claim 11, wherein the medicament contains the R-arylpropionic acid in an amount of 50 to 1000 mg/dose.

~~13.~~ Use according to claim 11, wherein the R-arylpropionic acid or R-arylpropionic acid derivative is essentially free of S-arylpropionic acids or S-arylpropionic acid derivatives.

~~14.~~ Use according to claim 11, wherein the R-arylpropionic acids are selected from those not metabolising to CoA thioesters, and especially are selected from R-flurbiprofen, R-ketoprofen, R-naproxen, R-tiaprofenic acid, and/or R-fenoprofen.

~~15.~~ Use according to claim 11, wherein the active material is present as alkali metal, alkaline earth metal, ammonium, amino acid salt, preferably as lysinate, megluminate, trometamine, arginate or aluminium salt.

~~16.~~ Use according to claim 11, wherein the medicament contains usual adjuvants and carrier materials.

~~17.~~ Use according to claim 11, wherein the medicaments are produced in the form of tablets, dragees or other orally usable forms.

~~18.~~ Use according to claim 11, wherein the active materials are used in rapidly inflowing, retardedly inflowing or combined in rapidly and retardedly inflowing form.